ARCHIVES

NCI Advisors Criticize a Biomarker Study Touted as High Priority for NCI and FDA.

This article is from The Cancer Letter archive.

Vol. 33 No. 27 | July 13, 2007

Download PDF Visit The Full Archive

Related Articles

In Brief: Reorganization Package Wending Its Way Through The Bureaucracy; FDA Seeks Names for Committee

November 30, 1979

In Brief: Satcher Names CDC Director; POG Appoints Monaco To Data Monitoring Committee

September 10, 1993

Flavopiridol Plus Cisplatin Tested In Phase II Trial

October 26, 2007

DeVita Emphasizes NCI Prevention In Statement To Senate Committee

February 15, 1980

New: Special Reports on the Dialogue and NCI’s 2015 goal posted at cancerletter.com.

August 8, 2003

Reports On Nutrition & Cancer Show Needs For More Clinical Studies

September 5, 1975